JoinClinicalTrials.com
Results
Hot
Post your clinical trial on JoinClinicalTrials.com
Ellijay, Georgia 30536
United States
Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
- NCT04122989Condition: Multiple Sclerosis
Intervention: Other: MS-SUPPORT
Sponsors: Shared Decision Making Resources; EMD Serono; Multiple Sclerosis Association of America; Multiple Sclerosis Alliance of Southern Colorado
Recruiting - NCT03604276Conditions: Subarachnoid Hemorrhage, Aneurysmal; Headache; Subarachnoid Hemorrhage
Intervention:
Sponsor: Maine Medical Center
Recruiting - NCT03289481Condition: Heart Failure With Normal Ejection Fraction
Interventions: Dietary Supplement: Active lozenge; Drug: Placebo
Sponsors: Penobscot Bay Medical Center; HumanN
Completed - NCT03219294Condition: Arthropathy of Hip
Interventions: Drug: Vecuronium 0.1 mg/kg; Drug: Vecuronium 0.2mg/kg
Sponsors: Craig Curry; Maine Medical Center; Spectrum Medical Group Anesthesiology
Completed - NCT04094857Condition: Cardiac Arrest
Intervention: Drug: HBN-1
Sponsor: Hibernaid, Inc
Not yet recruiting - NCT03771235Conditions: Tourette Syndrome; Persistent Tic Disorder
Interventions: Behavioral: Mindfulness-based Intervention for Tics; Behavioral: Tic Information and Coping Strategies
Sponsors: Bowdoin College; Massachusetts General Hospital
Recruiting - NCT03525626Conditions: Tourette Syndrome; Tic Disorders
Intervention: Behavioral: Online Mindfulness-based Tic Reduction
Sponsors: Bowdoin College; Massachusetts General Hospital
Completed - NCT04180176Conditions: Non-Small Cell Lung Cancer (NSCLC); Small-Cell Lung Cancer (SCLC)
Intervention: Other: Blood Draw
Sponsors: Genentech, Inc.; Flatiron Health, Inc.; Foundation Medicine, Inc.
Not yet recruiting - NCT03833388Condition: Dry Eye Syndrome
Interventions: Drug: TOP1630 0.1% Ophthalmic Solution TID OU; Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Sponsor: Topivert Pharma Ltd
Completed - NCT02486211Conditions: Coma; Heart Arrest; Anoxia
Interventions: Drug: Amantadine; Drug: Placebo
Sponsors: Jon Rittenberger, MD; American Heart Association
Completed - NCT04084483Condition: Dry Eye Disease
Interventions: Drug: K-161; Other: Placebo (Vehicle)
Sponsor: Kowa Research Institute, Inc.
Recruiting - NCT03961568Condition: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Intervention: Drug: Cenobamate
Sponsor: SK Life Science, Inc.
Enrolling by invitation - NCT02617667Condition: Dry Eye Syndromes
Interventions: Drug: Cyclosporine A; Drug: Placebo
Sponsor: Novaliq GmbH
Completed - NCT01234766Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine; Drug: Rituximab; Radiation: Y-90 ibritumomab
Sponsors: Dartmouth-Hitchcock Medical Center; Cephalon; Spectrum Pharmaceuticals, Inc
Active, not recruiting - NCT03737981Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Observation; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03633331Conditions: Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Palbociclib; Drug: Letrozole; Drug: Fulvestrant; Other: Questionnaire Administration; Other: Quality-of-Life Assessment
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting - NCT03959696Condition: Colorectal Cancer Screening
Interventions: Behavioral: Notification; Behavioral: Training
Sponsors: Massachusetts General Hospital; Maine Medical Center; Brigham and Women's Hospital; Newton-Wellesley Hospital; North Shore Medical Center
Enrolling by invitation - NCT03580928Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Venetoclax; Drug: Obinutuzumab; Drug: Acalabrutinib
Sponsors: Dana-Farber Cancer Institute; Acerta Pharma, LLC; Genentech, Inc.
Recruiting - NCT01960010Condition: Dry Eye Syndromes
Interventions: Drug: MIM-D3 Ophthalmic Solution; Drug: Vehicle
Sponsor: Mimetogen Pharmaceuticals USA, Inc.
Completed - NCT03952585Conditions: Basaloid Squamous Cell Carcinoma; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Drug: Cisplatin; Radiation: Image Guided Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT03811002Conditions: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Atezolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT03775265Conditions: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Bladder Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
Interventions: Drug: Atezolizumab; Drug: Cisplatin; Drug: Fluorouracil; Drug: Gemcitabine; Drug: Mitomycin; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Other: Survey Administration
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03768414Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - NCT03851445Condition: Previously Treated Non-Small Cell Lung Cancer
Intervention: Drug: Screening Platform
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - NCT03371719Conditions: PSA Progression; Stage III Prostate Adenocarcinoma; Stage IV Prostate Adenocarcinoma
Interventions: Drug: Apalutamide; Radiation: External Beam Radiation Therapy; Other: Placebo
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT03499808Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Biological: Isatuximab; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - NCT03244384Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions: Other: Clinical Observation; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03382561Conditions: Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT03055013Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting - NCT02954874Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT02927249Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting - NCT03092674Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts-2
Interventions: Drug: Azacitidine; Drug: Cytarabine; Drug: Decitabine; Other: Laboratory Biomarker Analysis; Drug: Midostaurin; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Suspended - NCT02912559Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT02750826Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting - NCT02785952Conditions: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT02595944Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Intervention: Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02997228Conditions: Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT02488967Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT02465060Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03488693Condition: Breast Cancer
Interventions: Radiation: Radiation; Other: No Radiation
Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group
Recruiting - NCT02194738Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Resectable Lung Non-Small Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT02193282Conditions: EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo Administration
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT02196181Conditions: BRAF V600E Mutation Present; BRAF V600K Mutation Present; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02154490Conditions: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Drug: Docetaxel; Biological: Durvalumab; Drug: Erlotinib Hydrochloride; Drug: FGFR Inhibitor AZD4547; Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Drug: Palbociclib; Other: Pharmacological Study; Biological: Rilotumumab; Drug: Talazoparib; Drug: Taselisib; Biological: Tremelimumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT02032823Condition: Breast Cancer
Interventions: Drug: Olaparib; Drug: Placebo
Sponsors: AstraZeneca; Breast International Group; Frontier Science & Technology Research Foundation, Inc.; NRG Oncology; Myriad Genetic Laboratories, Inc.; Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet; Merck Sharp & Dohme Corp.
Active, not recruiting - NCT02364557Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer
Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT03033576Conditions: Advanced Melanoma; Melanoma of Unknown Primary; Mucosal Melanoma; Refractory Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma; Unresectable Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT01674140Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: everolimus; Drug: exemestane; Drug: goserelin acetate; Drug: letrozole; Drug: leuprolide acetate; Drug: tamoxifen citrate; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT01863550Condition: Plasma Cell Myeloma
Interventions: Drug: Bortezomib; Drug: Carfilzomib; Drug: Dexamethasone; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Other: Quality-of-Life Assessment
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Active, not recruiting - NCT01594333Condition: Cardiovascular Disease
Interventions: Drug: Methotrexate; Drug: Placebo
Sponsors: Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI)
Completed - NCT02115282Conditions: Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Entinostat; Drug: Exemestane; Drug: Goserelin; Drug: Goserelin Acetate; Other: Placebo Administration; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02019264Conditions: Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes
Interventions: Drug: Lorcaserin hydrochloride; Drug: Placebo
Sponsors: Eisai Inc.; Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
Completed - NCT01901094Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Suspended - NCT01272037Conditions: Ductal Breast Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma
Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Drug: Systemic Chemotherapy; Drug: Tamoxifen Citrate
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT03367702Condition: Stage II Prostate Adenocarcinoma
Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT03180268Conditions: Grade II Meningioma; Intracranial Meningioma
Interventions: Other: Clinical Observation; Radiation: Radiation Therapy
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT02929329Condition: Heart Failure
Interventions: Drug: Omecamtiv Mecarbil; Drug: Placebo
Sponsors: Amgen; Cytokinetics; Servier
Active, not recruiting - NCT02890355Conditions: Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02595905Conditions: Breast Carcinoma Metastatic in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma
Interventions: Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02506153Conditions: Metastatic Cutaneous Melanoma; Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Non-Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage III Mucosal Melanoma of the Head and Neck AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
Interventions: Biological: Ipilimumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00310180Conditions: Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7
Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen Citrate
Sponsors: National Cancer Institute (NCI); American College of Surgeons; Cancer and Leukemia Group B; NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - NCT02152982Conditions: Glioblastoma; Gliosarcoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Other: Quality-of-Life Assessment; Drug: Temozolomide; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02048813Conditions: Anemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Drug: Ibrutinib; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Other: Quality-of-Life Assessment; Biological: Rituximab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02004275Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc.
Recruiting - NCT01953588Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant; Drug: anastrozole
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Active, not recruiting - NCT00769379Condition: Ductal Breast Carcinoma In Situ
Interventions: Other: Laboratory Biomarker Analysis; Biological: Trastuzumab; Radiation: Whole Breast Irradiation
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting - NCT01950390Conditions: Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Interventions: Biological: Bevacizumab; Biological: Ipilimumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01903811Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib; Drug: Dexamethasone; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT01764633Condition: Dyslipidemia
Interventions: Biological: Evolocumab; Drug: Placebo
Sponsor: Amgen
Completed - NCT01575548Conditions: Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7
Interventions: Drug: Pazopanib Hydrochloride; Other: Pharmacological Study; Other: Placebo Administration; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00433511Conditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Biological: Bevacizumab; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Paclitaxel; Other: Placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; ECOG-ACRIN Cancer Research Group; North Central Cancer Treatment Group
Active, not recruiting - NCT01169337Conditions: Light Chain Deposition Disease; Smoldering Plasma Cell Myeloma
Interventions: Other: Clinical Observation; Drug: Lenalidomide; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00878709Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Puma Biotechnology, Inc.
Active, not recruiting - NCT00785291Conditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biological: Bevacizumab; Drug: Ixabepilone; Other: Laboratory Biomarker Analysis; Drug: Nab-paclitaxel; Drug: Paclitaxel; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT03984448Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03788746Condition: Urothelial Carcinoma
Intervention:
Sponsor: AstraZeneca
Recruiting - NCT03678025Conditions: Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Interventions: Drug: Abiraterone; Drug: Bicalutamide; Drug: Degarelix; Drug: Docetaxel; Drug: Flutamide; Drug: Goserelin Acetate; Drug: Histrelin Acetate; Drug: Leuprolide Acetate; Drug: Nilutamide; Procedure: Orchiectomy; Drug: Prednisone; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Procedure: Radical Prostatectomy; Drug: Triptorelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - NCT00217737Conditions: Colon Mucinous Adenocarcinoma; Colon Signet Ring Cell Adenocarcinoma; Lynch Syndrome; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7; Stage IIC Colon Cancer AJCC v7
Interventions: Biological: Bevacizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT03660826Conditions: Endometrial Undifferentiated Carcinoma; Endometrioid Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7
Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Drug: Olaparib
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting - NCT03199885Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Biological: Trastuzumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT03155997Condition: Breast Cancer
Interventions: Drug: Abemaciclib; Drug: Standard Adjuvant Endocrine Therapy
Sponsors: Eli Lilly and Company; NSABP Foundation Inc
Active, not recruiting - NCT02926911Conditions: DCIS; Ductal Carcinoma in Situ
Interventions: Other: Guideline Concordant Care; Other: Active Surveillance
Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; Duke University; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; New York University; Washington University School of Medicine
Recruiting - NCT02867813Condition: Dyslipidemia
Intervention: Biological: Evolocumab
Sponsor: Amgen
Active, not recruiting - NCT02839707Conditions: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Undifferentiated Carcinoma; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Ovarian Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); NRG Oncology
Suspended - A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)NCT02684006Condition: Renal Cell Cancer
Interventions: Drug: Avelumab (MSB0010718C); Drug: Axitinib (AG-013736); Drug: Sunitinib
Sponsor: Pfizer
Active, not recruiting - NCT02582879Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention:
Sponsors: Pharmacyclics LLC.; Janssen, LP
Active, not recruiting - NCT02502266Conditions: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Questionnaire Administration; Drug: Topotecan; Drug: Topotecan Hydrochloride
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT02446600Conditions: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Tumor; Ovarian Seromucinous Carcinoma; Ovarian Serous Tumor; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Carboplatin; Drug: Cediranib Maleate; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Pharmacological Study; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); AstraZeneca; NRG Oncology
Active, not recruiting - NCT02339571Conditions: Recurrent Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab; Biological: Sargramostim
Sponsor: National Cancer Institute (NCI)
Suspended - NCT02311933Conditions: Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Tamoxifen Citrate; Drug: Z-Endoxifen Hydrochloride
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02164916Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: irinotecan hydrochloride; Drug: vemurafenib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Roche-Genentech
Active, not recruiting - NCT01942135Condition: Metastatic Breast Cancer
Interventions: Drug: Palbociclib; Drug: Fulvestrant; Drug: Placebo
Sponsors: Pfizer; AstraZeneca
Active, not recruiting - NCT01856192Conditions: Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01835158Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Kidney Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Drug: Sunitinib Malate
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01415752Conditions: Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT01286272Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma
Interventions: Drug: Bendamustine Hydrochloride; Drug: Bortezomib; Radiation: Fludeoxyglucose F-18; Other: Laboratory Biomarker Analysis; Biological: Ofatumumab; Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01196390Conditions: Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Stage IB Esophageal Cancer AJCC v7; Stage IIA Esophageal Cancer AJCC v7; Stage IIB Esophageal Cancer AJCC v7; Stage IIIA Esophageal Cancer AJCC v7; Stage IIIB Esophageal Cancer AJCC v7
Interventions: Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Procedure: Therapeutic Conventional Surgery; Biological: Trastuzumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting - NCT00951496Conditions: Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Carcinoma; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7
Interventions: Biological: Bevacizumab; Drug: Carboplatin; Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting - NCT00942331Conditions: Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Prostate Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Stage IV Bladder Urothelial Carcinoma AJCC v7; Stage IV Prostate Cancer AJCC v7; Stage IV Renal Pelvis Cancer AJCC v7; Stage IV Ureter Cancer AJCC v7; Stage IV Urethral Cancer AJCC v7; Unresectable Urothelial Carcinoma
Interventions: Biological: Bevacizumab; Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00844649Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Albumin-bound paclitaxel (ABI-007); Drug: Gemcitabine
Sponsor: Celgene
Completed - NCT00644228Conditions: DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00601900Conditions: Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Questionnaire Administration; Drug: Tamoxifen Citrate
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT03244826Condition: Other Cancer
Interventions: Other: Shared Care; Other: Standard Care
Sponsor: Dana-Farber Cancer Institute
Recruiting - NCT04095364Conditions: Low Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Stage II Ovarian Cancer AJCC v8; Stage IIA Ovarian Cancer AJCC v8; Stage IIB Ovarian Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8
Interventions: Drug: Carboplatin; Drug: Letrozole; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT04094688Condition: Colorectal Adenocarcinoma
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Leucovorin Calcium; Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Drug: Irinotecan; Dietary Supplement: Cholecalciferol; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting - NCT03088813Condition: Small Cell Lung Cancer
Interventions: Drug: Irinotecan liposome injection; Drug: Topotecan
Sponsor: Ipsen
Recruiting - NCT03988114Condition: Metastatic Breast Cancer
Interventions: Drug: Abemaciclib; Drug: Nonsteroidal Aromatase Inhibitor (NSAI)
Sponsor: Eli Lilly and Company
Withdrawn - NCT03914612Conditions: Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Biological: Pembrolizumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT03793179Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8
Interventions: Drug: Carboplatin; Biological: Pembrolizumab; Drug: Pemetrexed
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03757949Condition: Bladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Dietary Supplement: Nutritional Intervention; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - NCT03737994Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Alectinib; Drug: Brigatinib; Drug: Carboplatin; Drug: Ceritinib; Drug: Cisplatin; Drug: Crizotinib; Drug: Ensartinib; Drug: Lorlatinib; Drug: Pemetrexed
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting - NCT03422003Condition: Breast Cancer
Intervention: Radiation: Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Patient-Centered Outcomes Research Institute
Recruiting - NCT03701308Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Uproleselan
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03698019Conditions: Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03473223Condition: Acute Coronary Syndrome
Interventions: Biological: Apolipoprotein A-I [human] (apoA-I); Other: Placebo
Sponsor: CSL Behring
Recruiting - NCT03456830Condition: Enteric Hyperoxaluria
Interventions: Drug: ALLN-177; Drug: Placebo
Sponsor: Allena Pharmaceuticals
Active, not recruiting - NCT03348631Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Uterine Corpus Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Tazemetostat
Sponsors: National Cancer Institute (NCI); NRG Oncology
Suspended - NCT03274687Conditions: Prostate Adenocarcinoma; Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
Interventions: Radiation: Hypofractionated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Active, not recruiting - NCT02921256Conditions: Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
Interventions: Drug: Capecitabine; Drug: Fluorouracil; Radiation: Intensity-Modulated Radiation Therapy; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Veliparib
Sponsors: National Cancer Institute (NCI); NRG Oncology
Suspended - NCT02856581Condition: Lung Carcinoma
Interventions: Drug: Varenicline; Drug: Placebo; Other: Tobacco Cessation Counseling
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Pfizer
Active, not recruiting - NCT02836873Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Bexagliflozin; Drug: Placebo
Sponsor: Theracos
Completed - NCT02834013Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT02783573Condition: Alzheimer's Disease
Interventions: Drug: Lanabecestat; Drug: Placebo
Sponsors: AstraZeneca; Eli Lilly and Company
Terminated - NCT02670083Condition: Alzheimer's Disease
Interventions: Drug: Crenezumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Completed - NCT02554890Condition: Acute Heart Failure
Interventions: Drug: sacubitril/valsartan (LCZ696); Drug: Enalapril; Drug: sacubitril/valsartan (LCZ696) matching placebo; Drug: enalapril matching placebo
Sponsor: Novartis Pharmaceuticals
Completed - NCT02547818Condition: Alzheimer's Disease
Interventions: Drug: ALZT-OP1a; Drug: ALZT-OP1b; Other: Placebo ALZT-OP1a; Other: Placebo ALZT-OP1b
Sponsors: AZTherapies, Inc.; PharmaConsulting Group; KCAS Bio; APCER Life Sciences
Active, not recruiting - NCT02513394Condition: Breast Cancer
Interventions: Drug: Palbociclib; Drug: Standard Adjuvant Endocrine Therapy
Sponsors: Alliance Foundation Trials, LLC.; Austrian Breast & Colorectal Cancer Study Group; NSABP Foundation Inc; PrECOG, LLC.; Breast International Group; Pfizer
Active, not recruiting - NCT02451137Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin glargine, 300 U/ml; Drug: Insulin glargine, 100 U/ml; Drug: Insulin detemir; Drug: Background Therapy
Sponsor: Sanofi
Completed - NCT02173379Conditions: Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis
Interventions: Device: Absorb BVS; Device: XIENCE
Sponsor: Abbott Medical Devices
Active, not recruiting - NCT02065791Conditions: Diabetes Mellitus, Type 2; Diabetic Nephropathy
Interventions: Drug: Canagliflozin; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; The George Institute for Global Health, Australia
Completed - NCT02027428Condition: Squamous Cell Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Abraxane (Induction); Drug: Carboplatin (Induction); Drug: Abraxane (Maintenance); Other: Best Supportive Care (Maintenance)
Sponsor: Celgene
Completed - NCT02003222Conditions: Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Biological: Blinatumomab; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin; Drug: Daunorubicin Hydrochloride; Drug: Dexamethasone; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Pegaspargase; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Active, not recruiting - NCT02003209Conditions: HER2/Neu Positive; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7
Interventions: Drug: Aromatase Inhibition Therapy; Drug: Carboplatin; Other: Cytology Specimen Collection Procedure; Drug: Docetaxel; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Biological: Pertuzumab; Other: Quality-of-Life Assessment; Procedure: Therapeutic Conventional Surgery; Biological: Trastuzumab; Radiation: Whole Breast Irradiation
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting - NCT01920711Condition: Heart Failure With Preserved Ejection Fraction
Interventions: Drug: LCZ696; Drug: Valsartan
Sponsor: Novartis Pharmaceuticals
Completed - NCT01900665Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab; Drug: Placebo
Sponsor: Eli Lilly and Company
Terminated - NCT01872975Conditions: Stage IB Breast Cancer; Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI
Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - NCT01822509Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient; Myeloproliferative Neoplasm; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01822496Conditions: Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions: Radiation: Radiation Therapy; Drug: Carboplatin; Drug: Cisplatin; Drug: Crizotinib; Drug: Erlotinib; Drug: Etoposide; Drug: Paclitaxel
Sponsors: National Cancer Institute (NCI); NRG Oncology
Terminated - NCT01772472Condition: Breast Cancer
Interventions: Drug: trastuzumab; Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; NSABP Foundation Inc; German Breast Group
Active, not recruiting - NCT01751906Conditions: Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis
Interventions: Device: Absorb BVS; Device: XIENCE
Sponsor: Abbott Medical Devices
Completed - NCT01687998Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; The Cleveland Clinic
Terminated - NCT01573442Conditions: Arthralgia; Breast Cancer; Hot Flashes; Musculoskeletal Complications; Sexual Dysfunction
Interventions: Drug: testosterone; Other: placebo
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Completed - NCT01535053Conditions: Choriocarcinoma; FIGO Stage I Gestational Trophoblastic Tumor; FIGO Stage II Gestational Trophoblastic Tumor; FIGO Stage III Gestational Trophoblastic Tumor; Hydatidiform Mole
Interventions: Biological: Dactinomycin; Drug: Leucovorin Calcium; Drug: Methotrexate; Other: Quality-of-Life Assessment
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT01498289Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: docetaxel; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Completed - NCT01439880Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab; Other: Standard of care
Sponsor: Amgen
Completed - NCT01420926Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Therapy-Related Acute Myeloid Leukemia
Interventions: Drug: Bortezomib; Drug: Decitabine; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01358877Condition: Breast Cancer
Interventions: Drug: 5-Fluorouracil; Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Doxorubicin; Drug: Epirubicin; Drug: Paclitaxel; Drug: Pertuzumab; Drug: Placebo; Drug: Trastuzumab
Sponsors: Hoffmann-La Roche; Genentech, Inc.; Breast International Group
Active, not recruiting - NCT01256398Conditions: Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Biological: Alemtuzumab; Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dasatinib; Drug: Daunorubicin Hydrochloride; Drug: Dexamethasone; Drug: Etoposide Phosphate; Biological: Filgrastim; Drug: Fludarabine Phosphate; Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Melphalan; Drug: Mercaptopurine; Drug: Methotrexate; Biological: Pegfilgrastim; Other: Pharmacological Study; Drug: Tacrolimus; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01253070Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation; Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11; Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Acute Promyelocytic Leukemia With PML-RARA; FLT3 Gene Mutation; Therapy-Related Acute Myeloid Leukemia
Interventions: Procedure: Biopsy; Procedure: Bone Marrow Aspiration; Drug: Cytarabine; Drug: Daunorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Drug: Sorafenib Tosylate
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01238211Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Core Binding Factor Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Dasatinib; Drug: Daunorubicin Hydrochloride; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01167712Conditions: Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinofibroma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Biological: Bevacizumab; Drug: Carboplatin; Procedure: Computed Tomography; Drug: Paclitaxel; Procedure: Therapeutic Conventional Surgery
Sponsors: National Cancer Institute (NCI); NRG Oncology
Active, not recruiting - NCT01145495Conditions: Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Biological: Rituximab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT01114269Conditions: Coronary Artery Disease; Left Ventricular Dysfunction; Sudden Cardiac Death
Intervention:
Sponsors: Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); Abbott Medical Devices; Northwestern University; Roche Diagnostics; Quintiles, Inc.
Active, not recruiting - NCT00892177Condition: Glioblastoma Multiforme
Interventions: Biological: bevacizumab; Drug: dasatinib; Other: placebo
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Completed - NCT00887146Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group
Recruiting - NCT00884741Conditions: Glioblastoma; Gliosarcoma; Supratentorial Glioblastoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Biological: Bevacizumab; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Temozolomide
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; NRG Oncology
Completed - NCT00770809Conditions: Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7
Interventions: Other: Laboratory Biomarker Analysis; Drug: Lapatinib Ditosylate; Drug: Paclitaxel; Biological: Trastuzumab
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00588770Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Major Salivary Gland Cancer AJCC v7; Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Laryngeal Verrucous Carcinoma AJCC v7; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Major Salivary Gland Cancer AJCC v7; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Cancer AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Laryngeal Verrucous Carcinoma AJCC v7; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Major Salivary Gland Cancer AJCC v7; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Cancer AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Laryngeal Verrucous Carcinoma AJCC v7; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVC Major Salivary Gland Cancer AJCC v7; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7; Stage IVC Oral Cavity Cancer AJCC v6 and v7; Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7; Tongue Carcinoma
Interventions: Biological: Bevacizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Docetaxel; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00540514Condition: Non-Small Cell Lung Carcinoma
Interventions: Drug: Albumin-bound paclitaxel; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Celgene
Completed - NCT00490139Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: Novartis Pharmaceuticals; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; Canadian Cancer Trials Group
Active, not recruiting - NCT00443274Condition: Breast Implant
Interventions: Other: NBIR Placeholder; Device: 410 Arm; Device: BIFs
Sponsor: Allergan
Active, not recruiting - NCT00390455Conditions: Estrogen Receptor Positive; HER2 Positive Breast Carcinoma; HER2/Neu Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Fulvestrant; Other: Laboratory Biomarker Analysis; Drug: Lapatinib Ditosylate; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00262847Conditions: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Fallopian Tube Carcinoma; Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab; Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Placebo; Other: Quality-of-Life Assessment
Sponsors: National Cancer Institute (NCI); NRG Oncology
Completed - NCT00262821Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); NCIC Clinical Trials Group; Gynecologic Oncology Group
Terminated - NCT00070499Condition: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Dasatinib; Drug: Imatinib Mesylate; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT00066690Conditions: Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Recurrent Breast Carcinoma; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer
Interventions: Drug: Exemestane; Other: Laboratory Biomarker Analysis; Procedure: Oophorectomy; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen; Drug: Triptorelin
Sponsors: International Breast Cancer Study Group; Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in SituNCT00003857Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; NRG Oncology
Active, not recruiting - NCT03850912Conditions: Other Cancer; Gastrointestinal Cancer; Thoracic Cancer; Gynecologic Cancer
Interventions: Other: eSyM App Usage; Other: SASS Questionnaire
Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI); RTI International; Baptist Memorial Health Care Corporation; Dartmouth-Hitchcock Medical Center; Maine Medical Center; West Virginia University; Lifespan
Recruiting - NCT03042104Conditions: Aortic Stenosis; Heart Diseases
Intervention: Device: Edwards SAPIEN 3 THV
Sponsor: Edwards Lifesciences
Recruiting - NCT02185417Condition: Hypertension
Interventions: Drug: Hydrochlorothiazide (HCTZ); Drug: Chlorthalidone
Sponsor: VA Office of Research and Development
Recruiting - NCT04066699Conditions: Lung Lesion(s) Requiring Evaluation; Pulmonary Metastasis; Pulmonary Nodule, Solitary; Peripheral Lung Lesions
Intervention: Procedure: Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.
Sponsor: Veran Medical Technologies
Recruiting - NCT03404115Condition: Dry Eye Syndrome
Interventions: Drug: Reproxalap Ophthalmic Solution (0.25%); Drug: Reproxalap Ophthalmic Solution (0.1%); Drug: Vehicle Ophthalmic Solution
Sponsor: Aldeyra Therapeutics, Inc.
Completed - NCT03907488Conditions: Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Dacarbazine; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Biological: Filgrastim; Biological: Nivolumab; Biological: Pegfilgrastim; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Vinblastine; Drug: Vinblastine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting - NCT03845296Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Intervention: Drug: Rucaparib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - NCT03377556Conditions: ATM Gene Mutation; ATR Gene Mutation; BARD1 Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; FANCC Gene Mutation; FANCD2 Gene Mutation; FANCF Gene Mutation; FANCM Gene Mutation; NBN Gene Mutation; PALB2 Gene Mutation; RAD51 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation; Recurrent Squamous Cell Lung Carcinoma; RPA1 Gene Mutation; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Talazoparib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - NCT01274338Conditions: Melanoma of Unknown Primary; Recurrent Melanoma; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Biological: Ipilimumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT03609021Conditions: Breast Carcinoma; Estrogen Receptor Negative; Progesterone Receptor Negative
Interventions: Procedure: Screening Mammography; Procedure: Biospecimen Collection
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting - NCT03744910Condition: Antibody-mediated Rejection
Interventions: Biological: Clazakizumab; Drug: Normal saline
Sponsors: Vitaeris INC; ICON Clinical Research
Recruiting - NCT03632135Condition: Recurrent Glioblastoma
Interventions: Diagnostic Test: ChemoID assay; Drug: Chemotherapy
Sponsor: Cordgenics, LLC
Recruiting - NCT03414684Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: Nivolumab
Sponsors: Dana-Farber Cancer Institute; Bristol-Myers Squibb
Recruiting - NCT03289039Condition: Breast Cancer
Interventions: Drug: Neratinib; Drug: Fulvestrant
Sponsors: Dana-Farber Cancer Institute; Puma Biotechnology, Inc.
Recruiting - NCT01627041Conditions: Acute Myeloid Leukemia; Adult Acute Basophilic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin Hydrochloride; Drug: Decitabine; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - NCT02764541Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Tamoxifen; Drug: Palbociclib; Drug: Endocrine Therapy
Sponsors: Dana-Farber Cancer Institute; Pfizer
Recruiting - NCT02441686Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Dana-Farber Cancer Institute; Millennium Pharmaceuticals, Inc.; Celgene
Active, not recruiting - NCT03587740Condition: Breast Cancer
Intervention: Drug: T-DM1
Sponsors: Dana-Farber Cancer Institute; Susan G. Komen Breast Cancer Foundation; Gateway for Cancer Research
Recruiting - NCT03534323Conditions: Chronic Lymphocytic Leukemia; Richter Syndrome
Interventions: Drug: Duvelisib; Drug: Venetoclax
Sponsors: Dana-Farber Cancer Institute; Verastem, Inc.
Recruiting - NCT04151563Condition: Carcinoma, Non-small Cell Lung
Interventions: Biological: nivolumab; Biological: ipilimumab; Drug: cabozantinib; Drug: docetaxel; Biological: ramucirumab; Drug: lucitanib
Sponsors: Bristol-Myers Squibb; Clovis Oncology, Inc.; Exelixis; Eli Lilly and Company
Not yet recruiting - NCT03855787Condition: Kidney Calculi
Intervention: Procedure: Ureteroscopy
Sponsors: Vanderbilt University Medical Center; University of Michigan; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Maine Medical Center; Mayo Clinic; Université de Montréal; University of California, Davis; University of California, San Diego; Indiana University
Recruiting - NCT03764735Condition: Dry Eye Syndrome
Interventions: Drug: Low Dose - SkQ1; Drug: High dose - SkQ1; Drug: SkQ1 (Vehicle)
Sponsors: Mitotech, SA; ORA, Inc.
Completed - NCT03180684Conditions: Vulvar High Grade Squamous Intraepithelial Lesion (HSIL); Vulvar Dysplasia; Vulvar Intraepithelial Neoplasia (VIN); VIN2; VIN3; Pre-cancerous Lesions of the Vulva; Human Papillomavirus (HPV)
Interventions: Biological: VGX-3100; Drug: Imiquimod 5% cream; Device: CELLECTRA™ 2000
Sponsor: Inovio Pharmaceuticals
Active, not recruiting - NCT01602380Condition: Hormone Receptor Positive Breast Cancer
Interventions: Drug: faslodex 500mg; Drug: arimidex 1mg; Drug: faslodex dummy; Drug: arimidex dummy
Sponsor: AstraZeneca
Active, not recruiting - NCT02393716Conditions: Abdominal Aortic Aneurysm; AAA
Interventions: Device: Endurant Evo AAA Stent Graft System; Procedure: Endovascular aneurysm repair (EVAR)
Sponsor: Medtronic Endovascular
Active, not recruiting - NCT03180502Conditions: 1p/19q Co-deletion; Anaplastic Astrocytoma; Diffuse Astrocytoma; Glioma; IDH1 Gene Mutation; IDH2 Gene Mutation; Oligoastrocytoma; Oligodendroglioma; WHO Grade III Glioma
Interventions: Radiation: IMRT (Intensity-Modulated Radiation Therapy); Radiation: Proton Beam Radiation Therapy; Drug: Temozolomide
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting - NCT04108156Condition: Diabetic Macular Edema
Interventions: Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab; Drug: Intravitreal Ranibizumab 0.5 mg Injection
Sponsor: Hoffmann-La Roche
Recruiting - NCT04102098Condition: Carcinoma, Hepatocellular
Interventions: Drug: Atezolizumab; Drug: Bevacizumab
Sponsor: Hoffmann-La Roche
Recruiting - NCT04068896Conditions: Pancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer; Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Ovarian Cancer; Head Neck Squamous Cell Carcinoma
Interventions: Biological: NGM120; Other: Placebo
Sponsor: NGM Biopharmaceuticals, Inc
Recruiting - NCT04045665Conditions: Atrial Fibrillation; Stroke; Bleeding
Interventions: Drug: Antiplatelet-only strategy; Drug: Oral Anticoagulant plus background antiplatelet therapy
Sponsors: Icahn School of Medicine at Mount Sinai; National Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical Center
Not yet recruiting - NCT04031885Condition: Metastatic Breast Cancer
Interventions: Drug: Abemaciclib; Drug: Fulvestrant; Drug: Standard Chemotherapy
Sponsor: Eli Lilly and Company
Recruiting - NCT03972709Conditions: Macular Degeneration, Age-Related; Geographic Atrophy
Interventions: Drug: RO7171009; Drug: Sham Control
Sponsor: Genentech, Inc.
Recruiting - NCT03941483Condition: Acute Kidney Injury (AKI)
Interventions: Drug: ASP1128; Drug: Placebo
Sponsor: Astellas Pharma Inc
Recruiting
Popular Now
